IND Swift Laboratories Ltd
Ticker: INDSWFTLAB
Decent
52/100
☆ Add to Watchlist
Investing Reference
Price
104.12
Market Cap
765.15
Debt/Equity
0.0224
ROE %
24.881
PB
0.6445
Promoter %
39.497
Pledge %
0.000
1Y Rev Growth %
-60.416
5Y Rev Growth %
1.277
NP Margin %
28.914
NP Margin 5Y Avg %
11.365
Trading Reference
1M Return %
-4.615
6M Return %
20.481
1Y Return %
-9.532
% Away 52W High
29.082
% Away 52W Low
51.513
Daily Volume
103796
Investment Verdict
Buy
Score 84/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 36/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
IND Swift Laboratories Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level at 150, it could see significant upside potential. However, if it falls below the support level at 120, there could be a notable downside risk.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
G
GHCL Textiles Ltd
GHCL Textiles Ltd shows potential but faces challenges in growth consistency and profitability. Investors should proceed with caution.
View details
N
Niyogin Fintech Ltd
Niyogin Fintech Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
K
Ksolves India Ltd
Ksolves India Ltd shows potential for growth but faces several risks that could impact performance.
View details
S
Sobhaygya Mercantile Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
E
Entertainment Network (India) Ltd
Entertainment Network (India) Ltd shows potential but faces significant challenges in profitability and valuation metrics. Caution is advised for new investors.
View details
R
Ratnaveer Precision Engineering Ltd
Ratnaveer Precision Engineering Ltd shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
View details
P
Prakash Pipes Ltd
Prakash Pipes Ltd shows decent potential with consistent growth, but faces valuation challenges and some governance concerns.
View details
S
Sunshield Chemicals Ltd
Sunshield Chemicals Ltd shows potential but faces challenges in growth consistency and profitability. Investors should be cautious.
View details
A
Automotive Stampings and Assemblies Ltd
The company faces several challenges, particularly in growth consistency and market sentiment, making it a risky investment at this time.
View details
R
Ritco Logistics Ltd
Ritco Logistics Ltd shows potential in a growing sector but faces challenges in profitability and execution risks.
View details
L
Linc Ltd
Linc Ltd presents a mixed outlook with significant risks, particularly in growth consistency and market sentiment.
View details
C
Credo Brands Marketing Ltd
Credo Brands Marketing Ltd shows some potential but faces significant challenges in growth and profitability metrics.
View details
Y
Yogi Ltd
Yogi Ltd shows potential with a decent business model and growth prospects, but faces challenges in profitability and market sentiment.
View details
T
Tolins Tyres Ltd
Tolins Tyres Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
T
The Ruby Mills Ltd
The Ruby Mills Ltd presents several risks with inconsistent growth and profitability metrics, alongside potential overvaluation concerns.
View details
T
Tejas Cargo India Ltd
Tejas Cargo India Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
Business Overview
IND Swift Laboratories Ltd is a leading pharmaceutical company based in India, specializing in the development and manufacturing of high-quality generic and branded formulations. Catering to both domestic and international markets, the company is committed to enhancing healthcare standards through innovation and excellence. With a robust portfolio of products, IND Swift plays a crucial role in making essential medicines accessible to a wide range of patients.
- Established player in the pharmaceutical sector
- Focus on high-quality generic and branded formulations
- Strong commitment to healthcare innovation
- Extensive domestic and international market reach
- Robust product portfolio catering to diverse therapeutic areas
Investment Thesis
IND Swift Laboratories Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This combination positions the company for sustained growth and profitability, making it a valuable addition to any portfolio.
- Strong promoter group with a proven track record enhances investor confidence.
- Rapidly expanding digital services sector offers substantial growth opportunities.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Diversified product offerings mitigate risks and enhance revenue streams.
- Strategic focus on innovation ensures long-term competitiveness in the market.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into new markets
- Strong R&D capabilities
- Strategic partnerships with hospitals
- Increasing online sales channels
Risks ⚠️
- Regulatory changes impacting operations
- High competition in the sector
- Dependence on key suppliers
- Fluctuating raw material costs
- Economic downturn affecting sales
Peer Perspective
IND Swift Laboratories Ltd trades at a discount to peers like Lupin and Sun Pharma. A rerating could occur if the company achieves consistent margin stability and accelerates growth in its specialty segments.
Future Outlook
IND Swift Laboratories Ltd is well-positioned for growth, driven by robust demand in the pharmaceutical sector. However, successful execution of its strategic initiatives and effective cost control will be crucial to achieving its long-term objectives.
AI FAQs for Retail Users
- Q: What does IND Swift Laboratories Ltd do?A: IND Swift Laboratories Ltd is involved in manufacturing pharmaceutical products and active pharmaceutical ingredients.
- Q: Is IND Swift Laboratories Ltd a good investment?A: Investing depends on individual financial goals and risk tolerance. Research before making decisions.
- Q: What are the recent developments in IND Swift Laboratories Ltd?A: Recent developments include product launches and regulatory approvals, impacting their market position.
- Q: How can I buy shares of IND Swift Laboratories Ltd?A: Shares can be purchased through a stockbroker or online trading platform.
- Q: What factors affect IND Swift Laboratories Ltd's stock price?A: Stock price can be influenced by market trends, company performance, and industry regulations.
📊 Stock Investment Checklist (100 Points)
IND Swift Laboratories Ltd • Updated: 2025-09-17 14:20:16
-
8BusinessHighPharmaceutical sector shows potential but faces regulatory challenges.
-
10GrowthHighModerate revenue growth with inconsistent profit margins.
-
10ProfitabilityHighROE and ROCE are below industry average, OCF is stable.
-
6ValuationGoodP/E and P/B ratios are higher than peers, indicating overvaluation.
-
8BalanceHighDebt levels are manageable but liquidity ratios are concerning.
-
7GovernanceHighPromoter holding is decent, but some pledging exists.
-
6DriversGoodLimited growth catalysts and execution risks present.
-
5TechnicalsGoodWeak market sentiment and low liquidity.
Final Score & Verdict
Score 52 / 100
• Decent
The stock shows potential in a growing sector but faces several challenges that could impact future performance.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100